IP Library Granted Patent US 10,815,538
Granted Patent B2
US 10,815,538 · App. 16/155,594 · Granted Oct 27, 2020

Compositions and assays to detect seasonal H3 influenza A virus nucleic acids

Inventor: Ejan Tyler (Carlsbad, CA)
Assignee: Gen-Probe Prodesse, Inc.
C12Q1/701C12Q1/6851C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,815,538
App. No.
16/155,594
Granted
Oct 27, 2020
Kind
B2
Abstract

Methods for detecting the presence or absence of the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acids in biological samples are disclosed. Compositions that are target-specific nucleic acid sequences and kits comprising target-specific nucleic acid oligomers for amplifying in vitro the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acid and detecting amplified nucleic acid sequences are disclosed.

Claims (35)

1. A composition comprising: (a) a first seasonal H3 influenza A-specific amplification primer selected from the group consisting of: SEQ ID NO:77, SEQ ID NO:88, SEQ ID SEQ ID NO:96, SEQ ID NO:99, and a nucleotide sequence 19-50 nucleotides in length, wherein the nucleotide sequence consists of SEQ ID NO:77, SEQ ID NO:88, SEQ ID NO:92, SEQ ID NO:96 or SEQ ID NO:99 at the 3′ end and one or more nucleotides at the 5′ end that do not encode a portion of the H3 protein of the H3 seasonal influenza A or a complementary sequence thereof, or a DNA equivalent thereof; (b) a second seasonal H3 influenza A-specific amplification primer selected from the group consisting of: SEQ ID NO:78, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:100, and a nucleotide sequence 18-50 nucleotides in length, wherein the nucleotide sequence consists of SEQ ID NO:78, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:100 at the 3′ end and one or more nucleotides at the 5′ end that do not encode a portion of the H3 protein of the H3 seasonal influenza A or a complementary sequence thereof, or a DNA equivalent thereof; and (c) a seasonal H3 influenza A-specific oligonucleotide detection probe comprising a nucleic acid sequence comprising at least 18 contiguous nucleotides encoding the H3 protein from seasonal H3 influenza A or a complementary sequence thereof, or a DNA equivalent thereof, wherein a detectable label is operably linked to the oligonucleotide detection probe.

2. The composition according to claim 1 wherein the oligonucleotide detection probe comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:90, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:98, SEQ ID NO:101, and SEQ ID NO:102, or an RNA equivalent thereof.

3. The composition according to claim 1 , wherein the first amplification primer, the second amplification primer, the oligonucleotide detection probe, or a combination thereof, has one or more nucleotides at the 5′ end that do not encode a portion of the H3 protein of the H3 seasonal influenza A or a complementary sequence thereof, or a DNA equivalent thereof.

4. The composition according to claim 2 , wherein said amplification primers are SEQ ID NO:99 and SEQ ID NO:100 and the nucleic acid sequence of said detection probe is SEQ ID NO:102.

5. The composition of claim 1 , wherein (a) the first amplification primer consists of: SEQ ID NO:77, SEQ ID NO:88, SEQ ID NO:92, SEQ ID NO:96, or SEQ ID NO:99, (b) the second amplification primer consists of SEQ ID NO:78, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, or SEQ ID NO:100; and (c) the oligonucleotide detection probe comprises SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:90, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:98, SEQ ID NO:101, or SEQ ID NO:102.

6. The composition of claim 1 , wherein

(a) the first amplification primer consists of SEQ ID NO:77 and the second amplification primer consists of SEQ ID NO:78;

(b) the first amplification primer consists of SEQ ID NO:88 and the second amplification primer consists of SEQ ID NO:89;

(c) the first amplification primer consists of SEQ ID NO:92 and the second amplification primer consists of SEQ ID NO:93;

(d) the first amplification primer consists of SEQ ID NO:96 and the second amplification primer consists of SEQ ID NO:97; or

(e) the first amplification primer consists of SEQ ID NO:99 and the second amplification primer consists of SEQ ID NO:100.

7. A kit comprising, in a suitable container, a composition according to claim 1 , and instructions for use of said composition in any assay for amplification of polynucleotides in a biological sample.

8. A method for the detection of an influenza A virus from a sample, comprising the steps of:

(a) contacting an influenza A virus nucleic acid from a sample with a composition according to claim 1 ;

(b) providing conditions for amplifying the nucleic acid from step a by a polymerase chain reaction to generate an amplification product from the nucleic acid; and

(c) detecting the presence or absence of amplification product from step b, wherein the presence of the amplification product indicates that the sample contained an influenza A virus.

9. The method according to claim 8 , wherein the detecting step is selected from the group consisting of a real-time detecting step and a taqman PCR detecting step.

10. The method of claim 8 , wherein at step (a) the influenza A virus nucleic acid is contacted with a composition according to one of Mixtures 2 to 5 and 16 to 23.

11. The method according to claim 10 , wherein the detecting step is selected from the group consisting of a real-time detecting step and a taqman PCR detecting step.

12. A method for the detection of a seasonal H3 Influenza A Virus from a sample, comprising the steps of:

(a) contacting a seasonal H3 Influenza A Virus nucleic acid from the sample with a primer pair comprising a first amplification primer and a second amplification primer wherein:

(i) the first amplification primer consists of SEQ ID NO:77 and the second amplification primer consists of SEQ ID NO:78;

(ii) the first amplification primer consists of SEQ ID NO:88 and the second amplification primer consists of SEQ ID NO:89;

(iii) the first amplification primer consists of SEQ ID NO:92 and the second amplification primer consists of SEQ ID NO:93;

(iv) the first amplification primer consists of SEQ ID NO:96 and the second amplification primer consists of SEQ ID NO:97; or

(v) the first amplification primer consists of SEQ ID NO:99 and the second amplification primer consists of SEQ ID NO:100,

(b) providing conditions for amplifying the nucleic acid from step (a) by a polymerase chain reaction to generate an amplification product from the nucleic acid; and

(c) detecting the presence or absence of amplification product from step (b), wherein the presence of the amplification product indicates that the sample contained a seasonal H3 Influenza A Virus.

13. The method according to claim 12 , wherein the detecting step is selected from the group consisting of a real-time detecting step and is a taqman PCR detecting step.

14. The method according to claim 12 , wherein the detecting step uses an oligonucleotide detection probe having a nucleic acid sequence selected from the group consisting of: SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:90, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:98, SEQ ID NO:101, and SEQ ID NO:102, or an RNA equivalent thereof.

15. The method according to claim 12 , wherein the amplifying step is a multiplex amplification reaction that further comprises a primer pair from Table 1, a primer pair from Table 2, or a primer pair from Table 1 and a primer pair from Table 2.

16. The method according to claim 15 , wherein the detecting step further comprises a probe from Table 1, a probe from Table 2, or a probe from Table 1 and a probe from Table 2.

17. The composition according to claim 3 , wherein the one or more nucleotides at the 5′ end encode a promoter sequence.

18. The composition according to claim 1 , wherein the detectable label comprises a fluorophore.

19. The composition according to claim 18 , wherein the oligonucleotide detection probe further comprises a quencher.

Assignments (5)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2020
From: GEN-PROBE INCORPORATED
To: GEN-PROBE PRODESSE, INC.
Reel/Frame 052668/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2020
From: TYLER, EJAN
To: GEN-PROBE INCORPORATED
Reel/Frame 052626/0092 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →